[Federal Register Volume 66, Number 182 (Wednesday, September 19, 2001)]
[Notices]
[Pages 48262-48263]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-23325]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare and Medicaid Services

[CMS-3075-N]


Medicare Program; Meeting of the Executive Committee of the 
Medicare Coverage Advisory Committee--October 17, 2001

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces a public meeting of the Executive 
Committee of the Medicare Coverage Advisory Committee (the Committee). 
The Committee will act on the recommendation of the Diagnostic Imaging 
panel regarding FDG Positron Emission Tomography (PET) imaging for 
breast cancer diagnosis and staging, and the recommendation of the 
Drugs, Biologics and Therapeutics panel regarding use of levocarntine 
in End Stage Renal Disease (ESRD) patients. Notice of this meeting is 
given under the Federal Advisory Committee Act (5 U.S.C. App. 2, 
section 10(a)(1) and (a)(2)).

DATES: The Meeting: October 17, 2001 from 8 a.m. until 4:30 p.m., 
E.D.T.
    Deadline for Presentations and Comments: October 3, 2001, 5 p.m., 
E.D.T.
    Special Accommodations: Persons attending the meeting who are 
hearing or visually impaired, and have a condition that requires 
special assistance or accommodations, are asked to notify the Executive 
Secretary by September 26, 2001 (see FOR FURTHER INFORMATION CONTACT).

[[Page 48263]]


ADDRESSES: The Meeting: The meeting will be held at the Centers for 
Medicare & Medicaid Services (CMS) headquarters, Multipurpose Room, 
7500 Security Blvd, Baltimore, MD 21244.
    Presentations and Comments: Submit formal presentations and written 
comments to Janet A. Anderson, Executive Secretary; Office of Clinical 
Standards and Quality; Centers for Medicare & Medicaid Services; 7500 
Security Boulevard; Mail Stop C1-09-06; Baltimore, MD 21244.
    Web site: You may access up-to-date information on this meeting at 
www.hcfa.gov/coverage.
    Hotline: You may access up-to-date information on this meeting on 
the CMS Medicare Advisory Committee Information Hotline, 1-877-449-5659 
(toll free) or in the Baltimore area (410) 786-9379.

FOR FURTHER INFORMATION CONTACT: Janet A. Anderson, Executive 
Secretary, (410) 786-2700.

SUPPLEMENTARY INFORMATION: On August 13, 1999, we published a notice in 
the Federal Register (64 FR 44231) to describe the Medicare Coverage 
Advisory Committee (Committee), which provides advice and 
recommendations to us about clinical issues. This notice announces the 
following public meeting of the Committee.

Current Panel Members

    Harold C. Sox, MD; Robert H. Brook, MD, ScD; Daisy Alford-Smith, 
PhD; Wade Aubry, MD; Linda Bergthold, PhD; Ronald M. Davis, MD; John H. 
Ferguson, MD; Leslie P. Francis, JD, PhD; Alan M. Garber, MD, PhD; 
Thomas V. Holohan, MA, MD, FACP; Joe W. Johnson, DC; Michael D. Maves, 
MD, MBA; Barbara McNeil, MD, PhD; Robert L. Murray, PhD; Frank 
Papatheofanis, MD, PhD; Randel E. Richner, MPH.

 Meeting Topic

    The Committee will act on the recommendation of the Diagnostic 
Imaging panel regarding FDG Positron Emission Tomography (PET) imaging 
for breast cancer diagnosis and staging, and the recommendation of the 
Drugs, Biologics and Therapeutics panel regarding use of levocarntine 
in End Stage Renal Disease (ESRD) patients.

Procedure and Agenda

    This meeting is open to the public. The Committee will hear oral 
presentations from the public for approximately 90 minutes. The 
Committee may limit the number and duration of oral presentations to 
the time available. If you wish to make a formal presentation you must 
notify the Executive Secretary named in the FOR FURTHER INFORMATION 
CONTACT section of this notice. In addition, the Executive Secretary 
must receive, by the Deadline for Presentations and Comments date 
listed in the DATES section of this notice, the names and addresses of 
proposed participants; a brief statement of the general nature of the 
evidence or arguments you wish to present; and a written copy of your 
presentation. We will request that you declare at the meeting whether 
or not you have any financial involvement with manufacturers of any 
items or services being discussed (or with their competitors).
    After the public and CMS presentations, the Committee will 
deliberate openly on the topic. Interested persons may observe the 
deliberations, but the Committee will not hear further comments during 
this time except at the request of the chairperson. The Committee will 
also allow approximately a 30-minute open public session for any 
attendee to address issues specific to the topic. At the conclusion of 
the day, the members will vote and the Committee will make its 
recommendation.

    Authority: 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).

(Catalog of Federal Domestic Assistance Program No. 93.774, 
Medicare--Supplementary Medical Insurance Program)


    Dated: September 5, 2001.
Jeffrey L. Kang,
Director, Office of Clinical Standards and Quality, Centers for 
Medicare & Medicaid Services.
[FR Doc. 01-23325 Filed 9-18-01; 8:45 am]
BILLING CODE 4120-01-P